Floatz logo

Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
DALPICICLIB ISETIONATE
Hepatocellular Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Dfn-15
CD5 Positive
Sun Yat-sen UniversityP2CCC (53)
Dfn-15
Diffuse Large B-Cell Lymphoma
Sun Yat-sen UniversityP2CCC (53)
Dfn-15
Microsatellite Instability High
Sun Yat-sen UniversityP2CCC (53)
Dfn-15
Mismatch Repair Deficiency
Sun Yat-sen UniversityP2CCC (53)
Dfn-15
Mismatch Repair-deficient (dMMR)
Sun Yat-sen UniversityP2CCC (53)
Dfn-15
Marinesco-Sjogren Syndrome
Sun Yat-sen UniversityP2CCC (53)
Docetaxel
Concurrent Chemoradiotherapy
Sun Yat-sen UniversityP2CCC (53)
Docetaxel
Consolidation Therapy
Sun Yat-sen UniversityP2CCC (53)
Docetaxel
Surufatinib
Sun Yat-sen UniversityP2CCC (53)
Docetaxel
Tislelizumab
Sun Yat-sen UniversityP2CCC (53)
Donafenib
Liver Cancer
Sun Yat-sen UniversityP2CCC (53)
Eloxatin
Chemoradiation
Sun Yat-sen UniversityP2CCC (53)
Eloxatin
Cytoreductive Surgery
Sun Yat-sen UniversityP2CCC (53)
Eloxatin
Hyperthermic Intraperitoneal Chemotherapy
Sun Yat-sen UniversityP2CCC (53)
Eloxatin
Neoadjuvant Chemoimmunotherapy
Sun Yat-sen UniversityP2CCC (53)
Ensartinib
Mutation
Sun Yat-sen UniversityP2CCC (53)
ETOPOSIDE
First-line Treatment
Sun Yat-sen UniversityP2CCC (53)
ETOPOSIDE
Toripalimab
Sun Yat-sen UniversityP2CCC (53)
FLUOROURACILUM
Cytoreductive Surgery
Sun Yat-sen UniversityP2CCC (53)
FLUOROURACILUM
Hyperthermic Intraperitoneal Chemotherapy
Sun Yat-sen UniversityP2CCC (53)
FLUOROURACILUM
Ivonescimab
Sun Yat-sen UniversityP2CCC (53)
Fluzoparib
Ovarian Endometrioid Adenocarcinoma
Sun Yat-sen UniversityP2CCC (53)
Fruquintinib
Anti-angiogenic Therapy
Sun Yat-sen UniversityP2CCC (53)
Fruquintinib
Second-line Treatment
Sun Yat-sen UniversityP2CCC (53)
Showing 176 to 200 of 470 assets
PreviousPage 8 of 19Next